Detail akcie Lantheus Hldgs online

Business Summary: Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lantheus Holdings Inc revenues decreased 1% to $1.13B. Net income decreased 45% to $179.5M. Revenues reflect PYLARIFY segment decrease of 5% to $748.9M, TechneLite segment decrease of 6% to $65.8M. Net income also reflects Investment in equity securities - unreal decrease of 99% to $871K (income), Other General and administrative increase of 56% to $169.4M (expense).